Surgalign Holdings (OTCPK:SRGA.Q) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

SRGA.Q Panoramica delle azioni

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide.

Informazioni sull'azienda

SRGA.Q analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	0/6
Dividendi	0/6

Premi

Analisi del rischio

Gli utili sono diminuiti del 9.6% all'anno negli ultimi 5 anni

Non ha una capitalizzazione di mercato significativa ( $165K )

Patrimonio netto negativo

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

+ 2 più rischi

Surgalign Holdings, Inc. Concorrenti

InVitro International

OTCPK:IVRO

US$1.2m

Procyon

OTCPK:PCYN

US$1.9m

Vycor Medical

OTCPK:VYCO

US$1.9m

Wearable Health Solutions

OTCPK:WHSI

US$182.7k

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Surgalign Holdings
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.018
Massimo di 52 settimane	US$4.00
Minimo di 52 settimane	US$0.005
Beta	1.49
1Variazione di 1 mese	63.64%
Variazione a 3 mesi	-80.00%
Variazione di 1 anno	-99.50%
3Variazione a 3 anni	-99.97%
Variazione a 5 anni	-99.99%
Variazione dall'IPO	-100.00%

Notizie e aggiornamenti recenti

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

Rendimenti per gli azionisti

	SRGA.Q	US Medical Equipment	US Mercato
7D	16.1%	1.2%	0.07%
1Y	-99.5%	12.1%	22.7%

Ritorno vs Industria: SRGA.Q ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento 11.2 % nell'ultimo anno.

Rendimento vs Mercato: SRGA.Q ha avuto una performance inferiore al mercato US che ha registrato un rendimento 25.6 % nell'ultimo anno.

Volatilità dei prezzi

Is SRGA.Q's price volatile compared to industry and market?
SRGA.Q volatility
SRGA.Q Average Weekly Movement	40.5%
Medical Equipment Industry Average Movement	8.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di SRGA.Q è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di SRGA.Q è aumentata da 28% a 40% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1997	240	Terry Rich	www.surgalign.com

Surgalign Holdings, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Surgalign Holdings con la sua capitalizzazione di mercato?
SRGA.Q statistiche fondamentali
Capitalizzazione di mercato	US$165.30k
Guadagni(TTM)	-US$50.49m
Ricavi(TTM)	US$78.12m

0.0x

Rapporto P/S

0.0x

Rapporto P/E

SRGA.Q è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
SRGA.Q Conto economico (TTM)
Ricavi	US$78.12m
Costo del fatturato	US$26.03m
Profitto lordo	US$52.09m
Altre spese	US$102.58m
Guadagni	-US$50.49m

Ultimi guadagni dichiarati

Mar 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-5.50
Margine lordo	66.68%
Margine di profitto netto	-64.63%
Rapporto debito/patrimonio netto	-54.1%

Come si è comportato SRGA.Q nel lungo periodo?

Vedi performance storica e confronto

SRGA.Q Panoramica delle azioni

Premi

Analisi del rischio

Surgalign Holdings, Inc. Concorrenti

OTCPK:IVRO

US$1.2m

OTCPK:PCYN

US$1.9m

OTCPK:VYCO

US$1.9m

OTCPK:WHSI

US$182.7k

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)